Butriptyline

Overview of the antidepressant drug Butriptyline

Butriptyline
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Butriptyline, also known by its trade name Evadyne, is a tricyclic antidepressant (TCA) that was developed in the 1960s. It is primarily used for the treatment of depression.

Pharmacology

Butriptyline is a member of the tricyclic antidepressant class, which works by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine in the brain. This action increases the levels of these neurotransmitters in the synaptic cleft, thereby enhancing mood and alleviating depressive symptoms.

Mechanism of Action

Chemical structure of Butriptyline

Butriptyline acts primarily as a serotonin-norepinephrine reuptake inhibitor (SNRI). It also has affinity for various receptors, including histamine and muscarinic receptors, which contributes to its side effect profile.

Clinical Use

Butriptyline is indicated for the treatment of major depressive disorder. It is less commonly used today due to the availability of newer antidepressants with more favorable side effect profiles.

Side Effects

Common side effects of Butriptyline include dry mouth, constipation, urinary retention, and sedation. Due to its anticholinergic properties, it may also cause blurred vision and tachycardia.

History

Butriptyline was first introduced in the 1960s. It was marketed under the trade name Evadyne. However, its use has declined over the years as newer antidepressants, such as SSRIs and SNRIs, have become more popular due to their improved safety and tolerability.

Related pages

• Tricyclic antidepressant
• Serotonin-norepinephrine reuptake inhibitor
• Depression (mood)